Stephen Odunayo Ikuerowo1, Alaba Fredrick Doherty2, Muftau Jimoh Bioku3, Abimbola Ayodeji Abolarinwa2, Adekunle Azeez Adebayo4, Steves Olaide Oyeleke4, Olufunmilade Akinfolarin Omisanjo1. 1. Department of Surgery, Urology Division, Lagos State University College of Medicine, Ikeja, Lagos, Nigeria; Department of Surgery, Urology Division, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria. 2. Department of Surgery, Urology Division, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria. 3. Department of Surgery, Urology Division, Federal Staff Medical Centre, Abuja, Nigeria. 4. Department of Anaesthesia, Lagos State University College of Medicine, Ikeja, Lagos, Nigeria.
Abstract
BACKGROUND: Prostate cancer is the most commonly diagnosed cancer in men in Nigeria and most cases present when the disease is already in an advanced stage. Radical prostatectomy for early prostate cancer is therefore not a commonly performed operation by urologists in Nigeria. We have had training and significant experience in radical retropubic prostatectomy. We, therefore, report the outcome of our initial experience. MATERIALS AND METHODS: We review the record of men with early prostate cancer who had radical retropubic prostatectomy in our institution from 2007 to 2015. RESULTS: There were 34 men who had radical retropubic prostatectomy in the 8-year period of review. The youngest and oldest patients were aged 50 and 71 years, respectively. The mean age was 64.2 years. All the patients were diagnosed following 12-core ultrasound-guided transrectal prostate biopsy for elevated serum prostate specific antigen (PSA). The mean serum PSA was 15.3 (range 8.5-100.3) ng/ml. The disease was pT1, pT2, and pT3 in 6, 20, and 8 patients respectively. General anesthesia was employed in 28 (82.4%) patients and combined epidural and subarachnoid block anesthesia for 6 (17.6%) patients. The total duration of operation was 128-252 min (mean = 160 min). No blood transfusion was given in 5 (14.7%) patients while each of the remaining 29 (85.3%) patients had 2-5 units of blood intra- or post-operatively. There was no perioperative mortality. Complications include operation-induced erectile dysfunction in 12 (35.3%), major urinary incontinence in 1 (2.9%), lymphocele in 2 (5.9%), and reoperation due to anastomotic leak and right ureteric injury in 1 (2.9%). After a median follow-up of 42 months, disease recurrence has occurred in 3 (8.8%) patients 1 (2.9%) of whom has died of diabetic renal failure. CONCLUSION: Radical prostatectomy can be safely performed in men with early prostate cancer in Nigeria and should be offered to suitable patients.
BACKGROUND:Prostate cancer is the most commonly diagnosed cancer in men in Nigeria and most cases present when the disease is already in an advanced stage. Radical prostatectomy for early prostate cancer is therefore not a commonly performed operation by urologists in Nigeria. We have had training and significant experience in radical retropubic prostatectomy. We, therefore, report the outcome of our initial experience. MATERIALS AND METHODS: We review the record of men with early prostate cancer who had radical retropubic prostatectomy in our institution from 2007 to 2015. RESULTS: There were 34 men who had radical retropubic prostatectomy in the 8-year period of review. The youngest and oldest patients were aged 50 and 71 years, respectively. The mean age was 64.2 years. All the patients were diagnosed following 12-core ultrasound-guided transrectal prostate biopsy for elevated serum prostate specific antigen (PSA). The mean serum PSA was 15.3 (range 8.5-100.3) ng/ml. The disease was pT1, pT2, and pT3 in 6, 20, and 8 patients respectively. General anesthesia was employed in 28 (82.4%) patients and combined epidural and subarachnoid block anesthesia for 6 (17.6%) patients. The total duration of operation was 128-252 min (mean = 160 min). No blood transfusion was given in 5 (14.7%) patients while each of the remaining 29 (85.3%) patients had 2-5 units of blood intra- or post-operatively. There was no perioperative mortality. Complications include operation-induced erectile dysfunction in 12 (35.3%), major urinary incontinence in 1 (2.9%), lymphocele in 2 (5.9%), and reoperation due to anastomotic leak and right ureteric injury in 1 (2.9%). After a median follow-up of 42 months, disease recurrence has occurred in 3 (8.8%) patients 1 (2.9%) of whom has died of diabetic renal failure. CONCLUSION: Radical prostatectomy can be safely performed in men with early prostate cancer in Nigeria and should be offered to suitable patients.
Prostate cancer is the most commonly diagnosed cancer in men worldwide1 and in Nigeria where most cases present when the disease is already in the advanced stage.234 However, with the improving awareness and prostate specific antigen (PSA) screening for the disease in Lagos, Nigeria, early cases of prostate cancer requiring radical curative operation are being seen.45 Radical prostatectomy is the gold standard for early prostate cancer6 and has been shown to reduce progression to metastasis and death from the disease in randomized controlled trials.7 However, open radical prostatectomy is technically one of the most difficult operations in the field of urology and most urologists in Nigeria and West Africa do not have the expertise and experience for this operation.89 The training of the authors included a significant experience in radical retropubic prostatectomy. We, therefore, report our initial experience on radical retropubic prostatectomy, which to the best of our knowledge is the first in Nigeria.
MATERIALS AND METHODS
We carried out a review of a prospectively collected data on all patients who underwent radical retropubic prostatectomy at our institution from October 2007 to September 2015. Data obtained included the patient's biodata, preoperative history (including preoperative erectile status) and clinical examination, imaging findings (computed tomography (CT) scan, magnetic resonance imaging (MRI), and isotope bone scan as available), type of anesthesia, length of operation, blood transfusion, postoperative complications, and the tumor characteristics. The data were analyzed using IBM-SPSS Statistics 21 (SPSS, Inc., Chicago, IL, USA).
RESULTS
The clinical and pathological features are summarized in Table 1. There were 34 men who had radical retropubic prostatectomy during the period. The ages were 50-71 years and a mean age of 64.2 years. The mean body weight was 79 (range 68-115) kg and the mean body mass index (BMI) was 28.5 (range 23.5-34.8) kg. Five (14.7%), 24 (70.6%), 5 (14.7%) men were classified as normal, overweight, and obese BMI categories respectively. All patients were asymptomatic for prostate cancer, and the diagnosis was made after 12-core systematic transrectal ultrasound-guided prostate biopsy for elevated serum PSA. Only 10 (29.4%) patients had preoperative lower urinary tract symptoms due to bladder outlet obstruction. Preoperative erectile dysfunction was present in 13 (38.2%) patients. The serum total PSA was 8.5-100.3 (mean 15.3) ng/mL. Two (5.9%) patients had serum PSA >20 ng/mL (50.2 and 100.5 ng/mL). Imaging for the further staging of cancer included CT scan of the pelvis or MRI of the prostate in 32 (94.1%) and isotope bone scan in 30 (88.2%) patients. The patients were staged as cT1 and cT2 disease in 8 (23.5%) and 26 (76.5%) patients respectively and N0 and N1 in 32 (94.1%) and 2 (5.9%) patients, respectively. None of the patients had any evidence of distant metastatic disease. All patients had adenocarcinoma of the prostate. Reported radical prostatectomy specimen Gleason scores were ≤6, 7 and 8-10 in 3 (8.8%), 22 (64.7%), and 9 (26.5%) patients, respectively. The postoperative pathological staging were pT1c, pT2, pT3 in 6 (17.7%), 20 (58.8%), and 8 (23.5%) respectively and pN0, pN1 in 32 and 2, respectively.
Table 1
Clinical and pathological features of all men who underwent radical retropubic prostatectomy
Clinical and pathological features of all men who underwent radical retropubic prostatectomyUnilateral nerve sparing radical retropubic prostatectomy was performed in 9 (26.5%), bilateral nerve sparing radical retropubic prostatectomy in 18 (52.9%), and no nerve sparing in 7 (20.6%) patients. General anesthesia was employed in 28 (82.4%) patients and combined epidural and subarachnoid block anesthesia for 6 (17.6%) patients. The latter was particularly useful in achieving postoperative analgesia. Bilateral pelvic (obturator) lymphadenectomy was routinely performed for all the patients before proceeding to prostatectomy. The total duration of operation was 128-252 min (mean = 160 min). No blood transfusion was given in 5 (14.7%) patients while each of the remaining 29 (85.3%) patients had 2-5 units of blood intra- or post-operatively. There was no perioperative mortality recorded. Urethral catheter was removed for 31 (91.2%) patients at 21st day postoperation after the cystogram showed no leakage. Three (8.8%) patients had catheterization for up to 6 weeks postoperation.Postoperative complications recorded were summarized in Table 2. Anastomotic leak and ureteric injury occurred each in 1 (4.2%) patient, and the patients had repair of the anastomotic leak and ureteric reimplantation. Two patients developed lymphocele, one of which resolved spontaneously by 10th postoperative day and the other had percutaneous drainage of the lymphocele and instillation of sclerosant. In addition, 1 (2.9%) had bladder neck stenosis that responded well to bouginage.
Table 2
Complications following radical retropubic prostatectomy
Complications following radical retropubic prostatectomyUrinary incontinence was recorded in 5 (20.8%) patients (1 continuous and 4 stress incontinence) persisting beyond 6 weeks after removal of the urethral catheter. Among the 21 patients who had no preoperative erectile dysfunction, 12 (51.7%) developed postoperative erectile dysfunction.The follow-up period ranged from 3 to 96 (median = 42) months. Biochemical recurrence with elevated serum PSA has been recorded in 3 patients at 24, 38 and 62 postoperative months, respectively. The first patient had who had preoperative PSA of 15.5 ng/mL and pathological stage of pT2bN0M0 was found to have PSA rise up to 8 ng/mL at 24 postoperative months and was commenced on goserelin. The other two patients were those who had preoperative serum PSA of >50 ng/ml and pathological stage T3N1M0. The first patient had bilateral orchidectomy, and the serum PSA has remained <0.1 ng/mL 4 years after (7 years after radical prostatectomy). The second patient had postoperative radiotherapy and goserelin. This patient died 6 years postradical prostatectomy from complications of diabetes. However, no prostate cancer-specific mortality has been recorded.
DISCUSSION
Radical prostatectomy is performed for clinically localized prostate cancer, usually discovered through PSA screening.6 Although screening for prostate cancer is currently controversial, it is recommended that annual PSA and digital rectal examination screening should be carried out among high-risk individuals such as black men with life expectancy ≥10 years. Although there is no formal screening program for prostate cancer in Nigeria, there is an annual public awareness campaign in Lagos state. This has resulted in identifying some early cases of prostate cancer suitable for radical prostatectomy, and they form a significant part of our series of radical prostatectomy.4Prostate cancer is known to have poorer clinical and pathological features among men of African descent, but access to curative surgery for localized disease in West African is very limited.101112 There has been no report of radical retropubic prostatectomy, one of the most major operations performed in urology, anywhere in Nigeria. This is largely because most cases of prostate cancer present in the advanced stage. Those cases that present early are rarely offered radical prostatectomy due to limited expertise and experience in our environment. In this study, only 34 cases were reported over an 8-year period, and this underscores the low prevalence of radical prostatectomy in our environment.The mean age among our patients is comparable to other reports from populations of African descent.912 However, many of our patients are men who were asymptomatic but discovered from routine screening, unlike these previous studies.912 The mean serum PSA of 15.4 ng/mL was quite similar but slightly lower than what was reported from similar study in Ghana (16.1 ng/mL) and much higher than that from West Indies (10.1 ng/mL).13 Good cancer control has been achieved following radical prostatectomy among our patients. Only in three patients have disease recurrence been recorded and no patient has died directly from prostate cancer. The only death recorded is from complication of diabetes.The operation time has progressively been reducing as we perform more cases. Obesepatients tend to have a more difficult surgery and therefore higher operation time. Our mean operation time of 160 min is comparable to what is obtained in already established centers, but our transfusion rate of 85.3% is rather high. This may be due to the initial experience of both the surgical and anesthetic teams. A previous study reported a transfusion rate drop from 88.8% in 1998 to 9.1% in 2002 after defining a transfusion trigger.14 We, therefore, expect a reduction in transfusion rate as we gain more experience. Although majority of the patients were operated under general anesthesia, the use of combined subarachnoid and epidural block was particularly beneficial for postoperative analgesia and therefore would be recommended for radical prostatectomy. The complications we recorded are comparable to what has been reported elsewhere, but we expect a reduction as we gather more cases.612131516
CONCLUSION
Radical prostatectomy is feasible in our setting with good oncological outcomes and few complications. The operation should be offered to suitable patients with localized prostate cancer in our environment.
Authors: Christina Fitzmaurice; Daniel Dicker; Amanda Pain; Hannah Hamavid; Maziar Moradi-Lakeh; Michael F MacIntyre; Christine Allen; Gillian Hansen; Rachel Woodbrook; Charles Wolfe; Randah R Hamadeh; Ami Moore; Andrea Werdecker; Bradford D Gessner; Braden Te Ao; Brian McMahon; Chante Karimkhani; Chuanhua Yu; Graham S Cooke; David C Schwebel; David O Carpenter; David M Pereira; Denis Nash; Dhruv S Kazi; Diego De Leo; Dietrich Plass; Kingsley N Ukwaja; George D Thurston; Kim Yun Jin; Edgar P Simard; Edward Mills; Eun-Kee Park; Ferrán Catalá-López; Gabrielle deVeber; Carolyn Gotay; Gulfaraz Khan; H Dean Hosgood; Itamar S Santos; Janet L Leasher; Jasvinder Singh; James Leigh; Jost B Jonas; Jost Jonas; Juan Sanabria; Justin Beardsley; Kathryn H Jacobsen; Ken Takahashi; Richard C Franklin; Luca Ronfani; Marcella Montico; Luigi Naldi; Marcello Tonelli; Johanna Geleijnse; Max Petzold; Mark G Shrime; Mustafa Younis; Naohiro Yonemoto; Nicholas Breitborde; Paul Yip; Farshad Pourmalek; Paulo A Lotufo; Alireza Esteghamati; Graeme J Hankey; Raghib Ali; Raimundas Lunevicius; Reza Malekzadeh; Robert Dellavalle; Robert Weintraub; Robyn Lucas; Roderick Hay; David Rojas-Rueda; Ronny Westerman; Sadaf G Sepanlou; Sandra Nolte; Scott Patten; Scott Weichenthal; Semaw Ferede Abera; Seyed-Mohammad Fereshtehnejad; Ivy Shiue; Tim Driscoll; Tommi Vasankari; Ubai Alsharif; Vafa Rahimi-Movaghar; Vasiliy V Vlassov; W S Marcenes; Wubegzier Mekonnen; Yohannes Adama Melaku; Yuichiro Yano; Al Artaman; Ismael Campos; Jennifer MacLachlan; Ulrich Mueller; Daniel Kim; Matias Trillini; Babak Eshrati; Hywel C Williams; Kenji Shibuya; Rakhi Dandona; Kinnari Murthy; Benjamin Cowie; Azmeraw T Amare; Carl Abelardo Antonio; Carlos Castañeda-Orjuela; Coen H van Gool; Francesco Violante; In-Hwan Oh; Kedede Deribe; Kjetil Soreide; Luke Knibbs; Maia Kereselidze; Mark Green; Rosario Cardenas; Nobhojit Roy; Taavi Tillmann; Taavi Tillman; Yongmei Li; Hans Krueger; Lorenzo Monasta; Subhojit Dey; Sara Sheikhbahaei; Nima Hafezi-Nejad; G Anil Kumar; Chandrashekhar T Sreeramareddy; Lalit Dandona; Haidong Wang; Stein Emil Vollset; Ali Mokdad; Joshua A Salomon; Rafael Lozano; Theo Vos; Mohammad Forouzanfar; Alan Lopez; Christopher Murray; Mohsen Naghavi Journal: JAMA Oncol Date: 2015-07 Impact factor: 31.777
Authors: Chad R Ritch; Belinda F Morrison; Greg Hruby; Kathleen C Coard; Richard Mayhew; William Aiken; Mitchell C Benson; James M McKiernan Journal: BJU Int Date: 2012-10-26 Impact factor: 5.588
Authors: Anna Bill-Axelson; Lars Holmberg; Hans Garmo; Jennifer R Rider; Kimmo Taari; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Anders Spångberg; Ove Andrén; Juni Palmgren; Gunnar Steineck; Hans-Olov Adami; Jan-Erik Johansson Journal: N Engl J Med Date: 2014-03-06 Impact factor: 91.245
Authors: Stephen Odunayo Ikuerowo; Olufunmilade Adefolarin Omisanjo; Muftau Jimoh Bioku; Michael Olawale Ajala; Victor Patrick Nonyelim Mordi; Julius Olusanmi Esho Journal: Pan Afr Med J Date: 2013-08-10
Authors: Mathew Yamoah Kyei; Edward James Mensah; Samuel Gepi-Attee; Devine Kwami; Kwabena Ampadu; Emmanuel Asante; George Oko Klufio; Edward Donkoh Yeboah Journal: ISRN Urol Date: 2013-04-24